Novo Nordisk A/S
Pagina dedicata companiei Novo Nordisk A/S listata cu simbolul US.NVO
Descriere companieModificare
Novo Nordisk A/S (https://www.novonordisk.com/) is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Grafic actiuni companieModificare
Ultimele stiri despre Novo Nordisk A/S (US.NVO)Modificare
- Radiografia companiilor din Romania in 2024 - 25 noiembrie 2025
- Industria pensiilor private din Romania - 06 noiembrie 2025
- Turbinele eoliene la turatie maxima - 06 octombrie 2025
- Constructiile isi continua cresterea - 19 septembrie 2025
- Risc ridicat de recesiune - 19 august 2025
- Cifra de afaceri din comertul cu amanuntul, in urcare - 07 august 2025
- Deficiturl bugetar la 6 luni - 30 iulie 2025
- Autorizatiile de construire in luna mai - 01 iulie 2025
- Profitul „excesiv”, taxat suplimentar - 25 iunie 2025
- Productia industriala in luna aprilie - 16 iunie 2025